Zobrazeno 1 - 1
of 1
pro vyhledávání: ''
Autor:
Jan Krejčí, František Salajka, Marek Minarik, Jindrich Finek, Libor Havel, Miloš Pešek, L Benesova, Michal Hrnčiarik, Ondřej Fiala, Zbyněk Bortlíček
Publikováno v:
Neoplasma. 60:676-682
Erlotinib is an epidermal growth factor receptor tyrosine-kinase inhibitor. Clinical trials have shown its efficacy in advanced non-small cell lung cancer (NSCLC). We conducted a large retrospective study based on clinical experience aiming to prove